Abstract Library

#4636 Maximising the use of pancreatic enzyme replacement therapy (PERT) among patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) and exocrine pancreatic insufficiency (EPI)

Introduction: Patients with GEPNENs frequently develop EPI due to surgical resection or use of somatostatin analogues (SSAs), however it is significantly underdiagnosed. Untreated EPI has significant impact on overall quality of life with patients with GEPNENs.

Conference:

Presenting Author:

Authors: Grewal U, Chandar A,

Keywords: Pancreatic insufficiency, Pancreatic enzyme replacement therapy, Gastroenteropancreatic neuroendocrine neoplasm,

#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs

Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.

Conference:

Presenting Author: Chan D

Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,

Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,

#4339 Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN)

Introduction: Accurate contouring for [68Ga]DOTATATE PET in NEN is challenging due to differing physiological uptake for the liver, spleen and other organs. This poses a significant problem for absolute thresholding algorithms using a single threshold, even if the threshold is based on liver uptake (as suggested for FDG PET by PERCIST). Improved contouring of PET to measure [68Ga]DOTATATE-avid tumour volume could help clinical translation of this potential biomarker.

Conference:

Presenting Author: Chan D

Authors: Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z,

Keywords: prognostic biomarker, PET imaging, [68Ga]DOTATATE, Total Lesion Volume,

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#4097 Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multicentre study

Introduction: 18F-FDG PET/CT avidity predicts for higher histological grade and worse prognosis in patients with NEN. However, there is less evidence regarding the role of FDG-avid tumor volume in predicting prognosis.

Conference:

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Conner A, Mileva M,

Keywords: prognostic biomarker, PET imaging, 18F-FDG, metabolic tumor volume,